Journey Medical reports FY2024 revenue $56.1M, net loss $14.7M; Emrosi launch underway

Journey Medical Corp

Total revenue $56.1M, down 29% YoY; product revenue net $55.1M (-8%) due to higher rebates and lower legacy volumes.
Net loss $14.7M ($0.72/sh) vs $3.9M loss prior year; adjusted EBITDA $0.8M vs $15.6M.
FDA approved Emrosi (minocycline) for rosacea Nov 2024; distribution started, first prescriptions filled, full promo expected April 2025.
Met all 2024 financial guidance: product revenue $55-60M, SG&A $39-42M, R&D $9-10M.
Non-GAAP adjusted EBITDA per share $0.04 basic, $0.03 diluted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.